近日，公司收到持股 5%以上股东和丰投资出具的《关于股份减持计划的告知函》。 现将相关情况公告如下： 证券代码：300519 证券简称：新光药业 公告编号：2025-017 浙江新光药业股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有浙江新光药业股份有限公司（以下简称 "公司"）股份 26,780,900 股（占 公司总股本比例 16.74%）的股东嵊州市和丰投资股份有限公司（以下简称"和丰投 资"）计划于本公告披露之日起 15 个交易日后的 3 个月内以集中竞价交易方式或 大宗交易方式共计减持其持有的不超过 4,800,000 股公司股份（即不超过公司总股 本的 3%）。其中：计划于本公告披露之日起 15 个交易日后的 3 个月内以集中竞价 交易方式减持其持有的不超过 1,600,000 股公司股份（即不超过公司总股本的 1%）； 计划于本公告披露之日起 15 个交易日后的 3 个月内 ...

Core Viewpoint - Zhejiang Xinguang Pharmaceutical Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 3.00 per share, totaling RMB 48 million, approved by the shareholders' meeting on May 13, 2025 [1][2]. Summary by Sections Profit Distribution Plan - The profit distribution plan involves a cash dividend of RMB 3.00 per 10 shares, amounting to a total cash distribution of RMB 48 million (including tax) [1]. - No capital reserve will be converted into share capital, and no bonus shares will be issued. The remaining undistributed profits will be carried forward to future years [1]. Dividend Taxation - For Hong Kong market investors, QFII, RQFII, and individual investors holding pre-IPO restricted shares, the cash dividend will be RMB 2.70 per 10 shares after tax [1]. - A differentiated tax rate will apply for individual shareholders based on their holding period when transferring shares, with specific tax amounts outlined for different holding durations [2]. Key Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2]. Distribution Method - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [2]. - The company assumes all legal responsibilities for any shortfall in cash dividends due to a decrease in shares held by shareholders during the distribution application period [2].

证券代码：300519 证券简称：新光药业 公告编号：2025-016 浙江新光药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 13 日召开的 2024 年度股东大会审议通过。现 将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司 2024 年度股东大会审议通过的 2024 年度利润分配方案为：以截至 2024 年 12 月 31 日公司总股本 16,000 万股为基数，向全体股东每 10 股派发现 金红利人民币 3.00 元（含税），合计派发现金红利人民币 48,000,000.00 元 （含税）。 本次利润分配不进行资本公积转增股本，不送红股，剩余未分配利润结转以 后年度分配。若在分配方案实施前，公司总股本发生变动的，公司将按照分配总 额不变的原则对分配比例进行调整。 2、自分配方案披露至实施期间，公司总股本未发生变化。 3、本次实施的分配方案与股东大会审议通过的分配方案 ...

上海市锦天城律师事务所 关于浙江新光药业股份有限公司 2024 年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所（以下简称"本所"）接受浙江新光药业股份有限 公司（以下简称"公司"）委托，就公司召开 2024 年度股东大会（以下简称"本 次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股东会规则》等法律、法规和其他规范性文件以及《浙江新光药业股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，审查了本所认为出具本法律意见书 ...

特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 证券代码：300519 证券简称：新光药业 公告编号：2025-015 浙江新光药业股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 3、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开情况 1、浙江新光药业股份有限公司（以下简称"公司"）2024 年度股东大会会 议通知已于 2025 年 4 月 21 日以公告形式发出，本次会议采用现场投票和网络 投票相结合的方式召开。公司于 2025 年 5 月 8 日发布了《关于召开 2024 年度股 东大会的提示性公告》（公告编号 2025-014），具体内容详见公司于中国证监 会指定信息披露网站发布的公告。 2、股权登记日：2025 年 5 月 6 日（星期二） 3、会议召开的日期和时间 （1）现场会议召开时间：2025 年 5 月 13 日（星期二）下午 14:00。 （2）网络投票时间：2025 年 5 月 13 日。其中，通过深圳证券交易所 ...

证券代码：300519 证券简称：新光药业 公告编号：2025-014 关于召开公司 2024 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开 第五届董事会第三次会议，审议通过了《关于提请召开公司 2024 年度股东大会 的议案》，并于 2025 年 4 月 21 日在巨潮资讯网（www.cninfo.com.cn）刊登了 《关于召开公司 2024 年度股东大会通知的公告》（公告编号 2025-012），决定 于 2025 年 5 月 13 日下午 14：00 召开公司 2024 年度股东大会。为进一步保护投 资者的合法权益，提示本公司股东行使股东大会表决权，完善本次股东大会的表 决机制，现发布关于召开 2024 年度股东大会的提示性公告。 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会。 2、股东大会召集人：公司董事会。公司第五届董事会第三次会议决定于 2025 年 5 月 13 日召开 2024 年度股东大会。 3、会议召开的合法 ...

Core Viewpoint - The AI headphone industry is transitioning from "audio tools" to "smart devices," emphasizing experience reconstruction over mere parameter upgrades [1][3]. Group 1: Market Trends - The AI headphone market is projected to grow over 7 times by 2024, characterized by features such as "voice interaction + local AI + health functions" [3]. - The competition in the sub-1000 yuan AI headphone market is intensifying, with various brands increasing their focus on technological innovation to stand out [6][7]. Group 2: Product Development - Future headphones are expected to evolve into multi-modal, multi-scenario composite terminals, serving as AI terminals, health assistants, and personal expression devices [3][5]. - Cleer's latest Clip headphones weigh only 40 grams, highlighting a trend towards lighter, more ergonomic designs [3]. Group 3: Technological Innovation - AI is becoming an essential "second brain" for headphones, enabling them to understand context, perform translations, transcribe notes, and monitor health [3][5]. - Cleer emphasizes a technology-driven approach, investing in R&D and establishing its own acoustic laboratory and product design center to enhance product differentiation [7]. Group 4: Consumer Preferences - Consumers are increasingly sensitive to the "value for money" aspect, making price wars less effective; instead, technological strength and product experience are key to enduring market cycles [7]. - The future of audio products will not see AI headphones completely replacing traditional headphones, but rather coexisting to meet diverse user needs across various scenarios [5].

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1500 | 0.1400 | 7.14 | 0.1900 | | 每股净资产（元） | 5.34 | 5.42 | -1.48 | 5.56 | | 每股公积金(元) | 1.01 | 1.01 | 0 | 1.01 | | 每股未分配利润(元) | 2.58 | 2.69 | -4.09 | 2.88 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.93 | 1.01 | -7.92 | 0.92 | | 净利润(亿元) | 0.25 | 0.23 | 8.7 | 0.3 | | 净资产收益率(%) | 2.91 | 2.67 | 8.99 | 3.48 | 数据四舍五入，查看更多财务数据>> 前十大流通股东累计持有： 4926.31万股，累计占流通股比： 43.17%，较上期变化： -12.16万股。 | 名称 | 持有数量 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥93,250,095.71, a decrease of 7.26% compared to ¥100,545,259.30 in the same period last year[5] - Net profit attributable to shareholders increased by 7.50% to ¥24,541,781.11 from ¥22,830,341.36 year-on-year[5] - Basic and diluted earnings per share both increased by 7.14% to ¥0.15 from ¥0.14 in the same period last year[5] - Total operating revenue for the current period is CNY 93,250,095.71, a decrease of 7.8% from CNY 100,545,259.30 in the previous period[20] - Net profit for the current period is CNY 24,541,781.11, up 7.5% from CNY 22,830,341.36 in the previous period[21] - Earnings per share increased to CNY 0.15 from CNY 0.14, representing a growth of 7.1%[22] Cash Flow - The net cash flow from operating activities rose by 7.60% to ¥41,825,265.23 compared to ¥38,871,503.24 in the previous year[5] - Cash flow from operating activities was CNY 99,159,239.63, compared to CNY 104,202,561.78 in the previous period[24] - Net cash flow from operating activities amounted to $41,825,265.23, an increase of 7.5% compared to $38,871,503.24 in the previous period[25] - Cash received from other operating activities increased by 268.31% to ¥8,640,620.62 compared to ¥2,346,013.10 in the same period last year[10] - Total cash outflow from operating activities was $65,974,595.02, a decrease of 2.5% from $67,677,071.64 year-over-year[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥923,934,006.86, reflecting a 1.56% increase from ¥909,781,335.37 at the end of the previous year[5] - Total current assets amount to 792,156,050.08 RMB, an increase from 774,713,254.45 RMB at the beginning of the period[17] - Total liabilities decreased to CNY 68,927,168.10 from CNY 79,249,505.77, a reduction of 13.0%[18] - Total equity increased to CNY 855,006,838.76 from CNY 830,531,829.60, reflecting a growth of 2.9%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,470[13] - The largest shareholder, Wang Yuejun, holds 38.25% of shares, totaling 61,200,000 shares[13] - The company has a total of 45,900,000 restricted shares held by Wang Yuejun, with no shares released during the period[15] Expenses - The company's financial expenses saw a significant increase of 337.67%, primarily due to increased bank interest income during the reporting period[9] - Total operating costs decreased to CNY 66,920,864.51 from CNY 76,153,559.49, reflecting a reduction of 12.5%[20] - Research and development expenses rose to CNY 4,277,457.45 from CNY 3,945,710.79, an increase of 8.4%[21] - Payments to employees increased to $11,686,571.92, up from $10,575,614.30, reflecting a rise of 10.5%[25] - Payments for taxes amounted to $13,434,788.30, slightly up from $13,214,297.95, indicating a marginal increase of 1.7%[25] Other Financial Metrics - The cash received from other operating activities was $8,640,620.62, compared to $2,346,013.10 in the prior period, indicating a significant increase[25] - Other comprehensive income after tax decreased to CNY -66,771.95 from CNY -407,242.18, indicating a reduction in losses[22] - Financial expenses showed a significant improvement, with a net income of CNY -8,267,487.56 compared to CNY -1,888,989.28 in the previous period[21] - Total cash inflow from investment activities was $95,881,420.44, down 9.5% from $106,261,564.38 year-over-year[25] - Cash outflow from investment activities totaled $80,839,886.25, a decrease of 13.3% compared to $93,235,040.60 in the prior period[25]

Overview of Operating Performance - The company reported a total revenue of 268 million yuan for 2024, a year-on-year decrease of 1.01% [1] - The net profit attributable to shareholders was 50.39 million yuan, down 21.7% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 45.39 million yuan, a decline of 24.5% year-on-year [1] - In Q4, the total revenue was 51.45 million yuan, a decrease of 5.23% year-on-year, while the net profit increased by 122.88% to 12.61 million yuan [1] Financial Indicators Analysis - The main products include Huangqi Shengmai Drink, Western Ginseng Oral Liquid, and Shenjindan Capsules, with Huangqi Shengmai Drink contributing 73.32% of main revenue at 196 million yuan and a gross margin of 34.13% [2] - Western Ginseng Oral Liquid accounted for 15.17% of main revenue at 40.60 million yuan, with a gross margin of 37.46% [2] - Shenjindan Capsules contributed 8.76% of main revenue at 23.45 million yuan, with a gross margin of 37.13% [2] Operating Situation Review - The company faced challenges in 2024, with declines in both total revenue and net profit [3] - However, the significant growth in net profit during Q4 indicates signs of recovery [3] - Huangqi Shengmai Drink remains the dominant product, while other products showed relatively weak performance [3] Future Development Outlook - The company will continue to focus on the pharmaceutical sector, particularly in traditional Chinese medicine, and will actively respond to national policies [4] - Plans include strengthening existing sales channels and exploring new ones to enhance marketing effectiveness [4] - The company aims to improve operational management to address industry policy changes and market competition pressures [4] Key Financial Metrics - Gross margin was 33.83%, down 18.04% year-on-year [6] - Net margin was 18.83%, a decrease of 20.9% year-on-year [6] - Earnings per share were 0.31 yuan, down 22.5% year-on-year [6] - Operating cash flow per share increased by 0.27% to 0.33 yuan [6] - Cash and cash equivalents totaled 503 million yuan, down 7.45% year-on-year [6] - Accounts receivable increased by 18.14% to 11.80 million yuan [6]